During 2021, Switzerland’s life sciences sector again played a major role in combating the COVID pandemic with two Swiss based companies developing in partnerships effective Covid-specific therapeutics (Humabs BioMed/Vir Biotechnology and Molecular Partners/Novartis).

 

In addition, Swiss life science companies also continued their work developing innovative solutions for other high unmet medical needs. This resulted in another year of very strong capital investments totaling CHF 3.33B from domestic and international sources and R&D investments aggregating to a new record of CHF 2.56B. The latest edition of the Swiss Biotech Report launched today by the Swiss Biotech Association in conjunction with EY and seven other partner organizations provides an analysis of the 2021 biotech funding as well as other 2021 key ratios and statistics compared to prior years.

 

Media release

Swiss Biotech Report 2022